IBS-D ENVIVA

Enviva is a Phase 2 clinical research study.
The goal of Enviva is to explore the effect of an investigational drug on the symptoms of irritable bowel syndrome with
predominant diarrhea (IBS-D).

Researchers are studying how the investigational drug may help ease unpleasant symptoms, such as abdominal pain,
bloating, and altered stool consistency.

Who can join the Enviva study?

18 years of age or older

Confirmed diagnosis of IBS-D

Have no expected changes to their lifestyle, exercise routine, and/or diet during study participation

Are willing to complete a daily diary of symptoms through a mobile app

What is the investigational drug?

The investigational drug, CIN-103, is a new formulation of a gastrointestinal drug called phloroglucinol. Phloroglucinol is
used outside of the United States to relieve painful spasms within the GI tract. The investigational drug is designed to
work similarly to help relieve symptoms of pain, cramping, and diarrhea by treating the painful spasms that occur in the
GI tract.